Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695305 · ClinicalTrials.gov registry record · Phase 2
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Phase 2 study of Atherosclerosis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 10
- Study locations
NCT00695305: Completed Phase 2 study of Atherosclerosis, sponsored by GlaxoSmithKline.
NCT00695305 is a Phase 2 study of Atherosclerosis that has completed, run by GlaxoSmithKline. The registered enrollment target is 83 participants, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00695305, a Phase 2 study of Atherosclerosis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 10
- Study locations
Study Summary
A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
Conditions Studied
Interventions
- DRUG placebo
- DRUG rilapladib
- OTHER 18F Fluorodeoxylucose (FDG)-PET
Study Locations (10)
New York
- GSK Investigational Site - New York
- GSK Investigational Site - New York
- GSK Investigational Site - New York
- GSK Investigational Site - New York
- GSK Investigational Site - North Massapequa
Massachusetts
- GSK Investigational Site - Boston
- GSK Investigational Site - Brockton
- GSK Investigational Site - Haverhill
New Jersey
- GSK Investigational Site - Linden
Rhode Island
- GSK Investigational Site - Warwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00695305 record still lists
NCT00695305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00695305 lists 10 locations in 4 states (New York, Massachusetts, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00695305 about?
NCT00695305 is a clinical study titled "An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks". A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
What is the current status of trial NCT00695305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2008-11. Estimated completion is 2010-05.
What conditions does trial NCT00695305 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT00695305?
The interventions under investigation include: placebo (DRUG), rilapladib (DRUG), 18F Fluorodeoxylucose (FDG)-PET (OTHER).
Who is sponsoring clinical trial NCT00695305?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00695305 being conducted?
This trial has 10 study locations across Massachusetts, New Jersey, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00695305's enrollment target sits among peer trials
83 54th of 69 higher than 16 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
VEAPS: Vitamin E Atherosclerosis Prevention Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia